(Another) New Drug Approved For Migraine Prevention

Ajovy is first anti-CGRP treatment available at monthly and quarterly doses 

The third new generation of CGRP antibody has been approved. It’s called Emgality (galcanezumab) which was just approved by the FDA on September 27th.

 

·         Watch this interview preview with Professor Lars Edvinsson, the inventor of the CGRP monoclonal antibodies.

 

·         Watch this interview preview with Professor Lars Edvinsson, the inventor of the CGRP monoclonal antibodies.

(2018-09-14)

Read the article in MigraineAgain.com >>>

 

Green Light – To Lilly’s Momoclonal Antibody To Migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab (Emgality) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month.

Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function

(2018-11-20)

Läs artikeln på EMHAnews.com >>>